EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Empagliflozin After Myocardial Infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI

Francesco Fioretti, Javed Butler, Jacob A Udell, W Schuyler Jones, Mark C Petrie, Josephine Harrington, Michaela Mattheus, Johann Bauersachs, Antoni Bayes-Genis, Shaun G Goodman, Tomasz Gasior, James L Januzzi und 12 weitere

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15393 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Francesco Fioretti und 23 weiteren Autor:innen. Beteiligte Einrichtung: Baylor Scott & White Research Institute, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the EMPACT-MI trial, empagliflozin did not reduce the primary endpoint of all-cause mortality or hospitalization for heart failure (HHF) following acute myocardial infarction (AMI) but was associated with a risk reduction for HF events.

Objectives

This study aimed to evaluate whether the effect of empagliflozin on HF events is consistent in patients with and without type 2 diabetes and/or chronic kidney disease enrolled in the EMPACT-MI trial.

Methods

Post hoc analysis assessing the effect of empagliflozin on the primary endpoint and on HF events in AMI patients with and without an established recommendation for a sodium–glucose cotransporter-2 inhibitor (SGLT2i) (type 2 diabetes or chronic kidney disease).

Results

Of 6522 participants, 3489 (53%) did not have type 2 diabetes and/or chronic kidney disease. Those without these conditions were younger and with fewer comorbidities. No differences were observed for the primary endpoint. Empagliflozin reduced time to first HHF, total HHF, time to adverse event (AE) of HF (including outpatient HF events) and total AEs of HF similarly in patients with and without type 2 diabetes or chronic kidney disease. Total HHFs were 50 and 63 [adjusted event rate 1.74 and 2.31 events per 100 patient-years; rate ratio (RR) 0.75; 95% confidence interval (CI) 0.48, 1.18] in patients without and 98 and 144 (adjusted event rate 3.91 and 6.04 events per 100 patient-years; RR 0.65; 95% CI 0.45, 0.94; P for interaction = 0.61) in those with type 2 diabetes or chronic kidney disease in the empagliflozin and placebo arms, respectively. Any AEs, serious AEs and AEs leading to permanent study drug discontinuation were similar between treatment groups in both subgroups.

Conclusions

Empagliflozin improved HF outcomes similarly in patients after AMI with or without type 2 diabetes or chronic kidney disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesRenal Insufficiency, ChronicDiabetes Mellitus, Type 2Myocardial InfarctionHeart FailureHumansMaleFemaleSodium-Glucose Transporter 2 InhibitorsAgedMiddle AgedTreatment OutcomeFollow-Up StudiesDouble-Blind Method

Stichwörter der Autor:innen

CKDSGLT2idiabetesheart failuremyocardial infarctionrecommendation

Substanzen

empagliflozinBenzhydryl CompoundsGlucosidesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Baylor Scott & White Research Institute, Dallas, Texas, USA.
  • Cardiology Unit, ASST Spedali Civili Hospital and University of Brescia, Brescia, Italy.
  • Women's College Hospital and Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, Toronto, Canada.
  • Division of Cardiology, Department of Medicine and Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
  • School of Cardiovascular and Medical Sciences, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
  • Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.

Förderung

  • Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance

Zitieren

APA

Fioretti, F., Butler, J., Udell, J. A., Schuyler Jones, W., Petrie, M. C., Harrington, J., Mattheus, M., Bauersachs, J., Bayes-Genis, A., Goodman, S. G., Gasior, T., Januzzi, J. L., Lopes, R. D., Ponikowski, P., Rossello, X., Schou, M., van der Meer, P., Vinereanu, D., Zieroth, S., …, & Anker, S. D. (2025). Empagliflozin After Myocardial Infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI. ESC Heart Failure. https://doi.org/10.1002/ehf2.15393

Vancouver

Fioretti F, Butler J, Udell JA, Schuyler Jones W, Petrie MC, Harrington J, et al. Empagliflozin After Myocardial Infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI. ESC Heart Failure. 2025. doi:10.1002/ehf2.15393

BibTeX
@article{Fioretti2025,
  author = {Fioretti, Francesco and Butler, Javed and Udell, Jacob A and Schuyler Jones, W and Petrie, Mark C and Harrington, Josephine and Mattheus, Michaela and Bauersachs, Johann and Bayes-Genis, Antoni and Goodman, Shaun G and Gasior, Tomasz and Januzzi, James L and Lopes, Renato D and Ponikowski, Piotr and Rossello, Xavier and Schou, Morten and van der Meer, Peter and Vinereanu, Dragos and Zieroth, Shelley and Brueckmann, Martina and Sumin, Mikhail and Bhatt, Deepak L and Hernandez, Adrian F and Anker, Stefan D},
  title = {Empagliflozin After Myocardial Infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15393}
}
Kostenlos starten →